Global Novel Coronavirus (COVID-19) Vaccine Market 2022 by Company, Regions, Type and Application, Forecast to 2028

  • receipt Report ID : 123143
  • calendar_today Published On: Mar, 2022
  • file_copy Pages: 156
  • list Technology
Buy @ $3500

The Novel Coronavirus (COVID-19) Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Novel Coronavirus (COVID-19) Vaccine market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.

Global key companies of Novel Coronavirus (COVID-19) Vaccine include Inovio Pharmaceuticals, Takis Biotech (Evvivax), Zydus Cadila, Codagenix, Inc., and GeoVax, Inc., etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation

Novel Coronavirus (COVID-19) Vaccine market is split by Type and by Application. For the period 2012-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

DNA

RNA

Others

Market segment by Application, can be divided into

Mild Symptom Patient

Critically Ill Patient

Market segment by players, this report covers

Inovio Pharmaceuticals

Takis Biotech (Evvivax)

Zydus Cadila

Codagenix, Inc.

GeoVax, Inc.

Bravovax

Janssen Pharmaceutical Companies

Altimmune

Vaxart

CanSino Biologics

ExpreS2ion Biotechnologies ApS

Clover Biopharmaceuticals

GSK

Vaxil Bio Ltd.

Generex

Novavax, Inc.

Sanofi Pasteur

Baylor

iBio, Inc.

Moderna, Inc.

Curevac

ImmunoPrecise

Market segment by regions, regional analysis covers

North America

Europe

Asia-Pacific (China, Japan, South Korea, Rest of Asia-Pacific)

South America

Middle East & Africa

The content of the study subjects, includes a total of 8 chapters:

Chapter 1, to describe Novel Coronavirus (COVID-19) Vaccine product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top players of Novel Coronavirus (COVID-19) Vaccine, with recent developments and future plans

Chapter 3, the Novel Coronavirus (COVID-19) Vaccine competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4, to break the market size data at the region level, with key companies in the key region and Novel Coronavirus (COVID-19) Vaccine market forecast, by regions, with revenue, from 2022 to 2028.

Chapter 5 and 6, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2022 to 2028.

Chapter 7 and 8, to describe Novel Coronavirus (COVID-19) Vaccine research findings and conclusion, appendix and data source.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Product Overview and Scope of Novel Coronavirus (COVID-19) Vaccine

1.2 Classification of Novel Coronavirus (COVID-19) Vaccine by Type

1.2.1 Overview: Global Novel Coronavirus (COVID-19) Vaccine Market Size by Type: 2022 Versus 2028

1.2.2 Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Type in 2028

1.2.3 DNA

1.2.4 RNA

1.2.5 Others

1.3 Global Novel Coronavirus (COVID-19) Vaccine Market by Application

1.3.1 Overview: Global Novel Coronavirus (COVID-19) Vaccine Market Size by Application: 2022 Versus 2028

1.3.2 Mild Symptom Patient

1.3.3 Critically Ill Patient

1.4 Global Novel Coronavirus (COVID-19) Vaccine Market Size & Forecast

1.5 Market Drivers, Restraints and Trends

1.5.1 Novel Coronavirus (COVID-19) Vaccine Market Drivers

1.5.2 Novel Coronavirus (COVID-19) Vaccine Market Restraints

1.5.3 Novel Coronavirus (COVID-19) Vaccine Trends Analysis

2 Company Profiles

2.1 Inovio Pharmaceuticals

2.1.1 Inovio Pharmaceuticals Details

2.1.2 Inovio Pharmaceuticals Major Business

2.1.3 Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product and Solutions

2.1.4 Inovio Pharmaceuticals Recent Developments and Future Plans

2.2 Takis Biotech (Evvivax)

2.2.1 Takis Biotech (Evvivax) Details

2.2.2 Takis Biotech (Evvivax) Major Business

2.2.3 Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Product and Solutions

2.2.4 Takis Biotech (Evvivax) Recent Developments and Future Plans

2.3 Zydus Cadila

2.3.1 Zydus Cadila Details

2.3.2 Zydus Cadila Major Business

2.3.3 Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Product and Solutions

2.3.4 Zydus Cadila Recent Developments and Future Plans

2.4 Codagenix, Inc.

2.4.1 Codagenix, Inc. Details

2.4.2 Codagenix, Inc. Major Business

2.4.3 Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions

2.4.4 Codagenix, Inc. Recent Developments and Future Plans

2.5 GeoVax, Inc.

2.5.1 GeoVax, Inc. Details

2.5.2 GeoVax, Inc. Major Business

2.5.3 GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions

2.5.4 GeoVax, Inc. Recent Developments and Future Plans

2.6 Bravovax

2.6.1 Bravovax Details

2.6.2 Bravovax Major Business

2.6.3 Bravovax Novel Coronavirus (COVID-19) Vaccine Product and Solutions

2.6.4 Bravovax Recent Developments and Future Plans

2.7 Janssen Pharmaceutical Companies

2.7.1 Janssen Pharmaceutical Companies Details

2.7.2 Janssen Pharmaceutical Companies Major Business

2.7.3 Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Product and Solutions

2.7.4 Janssen Pharmaceutical Companies Recent Developments and Future Plans

2.8 Altimmune

2.8.1 Altimmune Details

2.8.2 Altimmune Major Business

2.8.3 Altimmune Novel Coronavirus (COVID-19) Vaccine Product and Solutions

2.8.4 Altimmune Recent Developments and Future Plans

2.9 Vaxart

2.9.1 Vaxart Details

2.9.2 Vaxart Major Business

2.9.3 Vaxart Novel Coronavirus (COVID-19) Vaccine Product and Solutions

2.9.4 Vaxart Recent Developments and Future Plans

2.10 CanSino Biologics

2.10.1 CanSino Biologics Details

2.10.2 CanSino Biologics Major Business

2.10.3 CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Product and Solutions

2.10.4 CanSino Biologics Recent Developments and Future Plans

2.11 ExpreS2ion Biotechnologies ApS

2.11.1 ExpreS2ion Biotechnologies ApS Details

2.11.2 ExpreS2ion Biotechnologies ApS Major Business

2.11.3 ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Product and Solutions

2.11.4 ExpreS2ion Biotechnologies ApS Recent Developments and Future Plans

2.12 Clover Biopharmaceuticals

2.12.1 Clover Biopharmaceuticals Details

2.12.2 Clover Biopharmaceuticals Major Business

2.12.3 Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product and Solutions

2.12.4 Clover Biopharmaceuticals Recent Developments and Future Plans

2.13 GSK

2.13.1 GSK Details

2.13.2 GSK Major Business

2.13.3 GSK Novel Coronavirus (COVID-19) Vaccine Product and Solutions

2.13.4 GSK Recent Developments and Future Plans

2.14 Vaxil Bio Ltd.

2.14.1 Vaxil Bio Ltd. Details

2.14.2 Vaxil Bio Ltd. Major Business

2.14.3 Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Product and Solutions

2.14.4 Vaxil Bio Ltd. Recent Developments and Future Plans

2.15 Generex

2.15.1 Generex Details

2.15.2 Generex Major Business

2.15.3 Generex Novel Coronavirus (COVID-19) Vaccine Product and Solutions

2.15.4 Generex Recent Developments and Future Plans

2.16 Novavax, Inc.

2.16.1 Novavax, Inc. Details

2.16.2 Novavax, Inc. Major Business

2.16.3 Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions

2.16.4 Novavax, Inc. Recent Developments and Future Plans

2.17 Sanofi Pasteur

2.17.1 Sanofi Pasteur Details

2.17.2 Sanofi Pasteur Major Business

2.17.3 Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Product and Solutions

2.17.4 Sanofi Pasteur Recent Developments and Future Plans

2.18 Baylor

2.18.1 Baylor Details

2.18.2 Baylor Major Business

2.18.3 Baylor Novel Coronavirus (COVID-19) Vaccine Product and Solutions

2.18.4 Baylor Recent Developments and Future Plans

2.19 iBio, Inc.

2.19.1 iBio, Inc. Details

2.19.2 iBio, Inc. Major Business

2.19.3 iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions

2.19.4 iBio, Inc. Recent Developments and Future Plans

2.20 Moderna, Inc.

2.20.1 Moderna, Inc. Details

2.20.2 Moderna, Inc. Major Business

2.20.3 Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions

2.20.4 Moderna, Inc. Recent Developments and Future Plans

2.21 Curevac

2.21.1 Curevac Details

2.21.2 Curevac Major Business

2.21.3 Curevac Novel Coronavirus (COVID-19) Vaccine Product and Solutions

2.21.4 Curevac Recent Developments and Future Plans

2.22 ImmunoPrecise

2.22.1 ImmunoPrecise Details

2.22.2 ImmunoPrecise Major Business

2.22.3 ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Product and Solutions

2.22.4 ImmunoPrecise Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Novel Coronavirus (COVID-19) Vaccine Revenue and Share by Players (2022 & 2028)

3.2 Novel Coronavirus (COVID-19) Vaccine Players Head Office, Products and Services Provided

3.3 Novel Coronavirus (COVID-19) Vaccine Mergers & Acquisitions

3.4 Novel Coronavirus (COVID-19) Vaccine New Entrants and Expansion Plans

4 Global Novel Coronavirus (COVID-19) Vaccine Forecast by Region

4.1 Global Novel Coronavirus (COVID-19) Vaccine Market Size by Region: 2022 VS 2028

4.2 Global Novel Coronavirus (COVID-19) Vaccine Market Size by Region, (2022-2028)

4.3 North America

4.3.1 Key Companies of Novel Coronavirus (COVID-19) Vaccine in North America

4.3.2 Current Situation and Forecast of Novel Coronavirus (COVID-19) Vaccine in North America

4.3.3 North America Novel Coronavirus (COVID-19) Vaccine Market Size and Prospect (2022-2028)

4.4 Europe

4.4.1 Key Companies of Novel Coronavirus (COVID-19) Vaccine in Europe

4.4.2 Current Situation and Forecast of Novel Coronavirus (COVID-19) Vaccine in Europe

4.4.3 Europe Novel Coronavirus (COVID-19) Vaccine Market Size and Prospect (2022-2028)

4.5 Asia-Pacific

4.5.1 Key Companies of Novel Coronavirus (COVID-19) Vaccine in Asia-Pacific

4.5.2 Current Situation and Forecast of Novel Coronavirus (COVID-19) Vaccine in Asia-Pacific

4.5.3 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Size and Prospect (2022-2028)

4.6 South America

4.6.1 Key Companies of Novel Coronavirus (COVID-19) Vaccine in South America

4.6.2 Current Situation and Forecast of Novel Coronavirus (COVID-19) Vaccine in South America

4.6.3 South America Novel Coronavirus (COVID-19) Vaccine Market Size and Prospect (2022-2028)

4.7 Middle East & Africa

4.7.1 Key Companies of Novel Coronavirus (COVID-19) Vaccine in Middle East & Africa

4.7.2 Current Situation and Forecast of Novel Coronavirus (COVID-19) Vaccine in Middle East & Africa

4.7.3 Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Market Size and Prospect (2022-2028)

5 Market Size Segment by Type

5.1 Global Novel Coronavirus (COVID-19) Vaccine Market Forecast by Type (2022-2028)

5.2 Global Novel Coronavirus (COVID-19) Vaccine Market Share Forecast by Type (2022-2028)

6 Market Size Segment by Application

6.1 Global Novel Coronavirus (COVID-19) Vaccine Market Forecast by Application (2022-2028)

6.2 Global Novel Coronavirus (COVID-19) Vaccine Market Share Forecast by Application (2022-2028)

7 Research Findings and Conclusion

8 Appendix

8.1 Methodology

8.2 Research Process and Data Source

8.3 Disclaimer

List of Tables

Table 1. Global Novel Coronavirus (COVID-19) Vaccine Revenue by Type, (USD Million), 2022 VS 2028

Table 2. Global Novel Coronavirus (COVID-19) Vaccine Revenue by Application, (USD Million), 2022 VS 2028

Table 3. Inovio Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 4. Inovio Pharmaceuticals Major Business

Table 5. Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product and Solutions

Table 6. Takis Biotech (Evvivax) Corporate Information, Head Office, and Major Competitors

Table 7. Takis Biotech (Evvivax) Major Business

Table 8. Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Product and Solutions

Table 9. Zydus Cadila Corporate Information, Head Office, and Major Competitors

Table 10. Zydus Cadila Major Business

Table 11. Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Product and Solutions

Table 12. Codagenix, Inc. Corporate Information, Head Office, and Major Competitors

Table 13. Codagenix, Inc. Major Business

Table 14. Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions

Table 15. GeoVax, Inc. Corporate Information, Head Office, and Major Competitors

Table 16. GeoVax, Inc. Major Business

Table 17. GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions

Table 18. Bravovax Corporate Information, Head Office, and Major Competitors

Table 19. Bravovax Major Business

Table 20. Bravovax Novel Coronavirus (COVID-19) Vaccine Product and Solutions

Table 21. Janssen Pharmaceutical Companies Corporate Information, Head Office, and Major Competitors

Table 22. Janssen Pharmaceutical Companies Major Business

Table 23. Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Product and Solutions

Table 24. Altimmune Corporate Information, Head Office, and Major Competitors

Table 25. Altimmune Major Business

Table 26. Altimmune Novel Coronavirus (COVID-19) Vaccine Product and Solutions

Table 27. Vaxart Corporate Information, Head Office, and Major Competitors

Table 28. Vaxart Major Business

Table 29. Vaxart Novel Coronavirus (COVID-19) Vaccine Product and Solutions

Table 30. CanSino Biologics Corporate Information, Head Office, and Major Competitors

Table 31. CanSino Biologics Major Business

Table 32. CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Product and Solutions

Table 33. ExpreS2ion Biotechnologies ApS Corporate Information, Head Office, and Major Competitors

Table 34. ExpreS2ion Biotechnologies ApS Major Business

Table 35. ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Product and Solutions

Table 36. Clover Biopharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 37. Clover Biopharmaceuticals Major Business

Table 38. Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product and Solutions

Table 39. GSK Corporate Information, Head Office, and Major Competitors

Table 40. GSK Major Business

Table 41. GSK Novel Coronavirus (COVID-19) Vaccine Product and Solutions

Table 42. Vaxil Bio Ltd. Corporate Information, Head Office, and Major Competitors

Table 43. Vaxil Bio Ltd. Major Business

Table 44. Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Product and Solutions

Table 45. Generex Corporate Information, Head Office, and Major Competitors

Table 46. Generex Major Business

Table 47. Generex Novel Coronavirus (COVID-19) Vaccine Product and Solutions

Table 48. Novavax, Inc. Corporate Information, Head Office, and Major Competitors

Table 49. Novavax, Inc. Major Business

Table 50. Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions

Table 51. Sanofi Pasteur Corporate Information, Head Office, and Major Competitors

Table 52. Sanofi Pasteur Major Business

Table 53. Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Product and Solutions

Table 54. Baylor Corporate Information, Head Office, and Major Competitors

Table 55. Baylor Major Business

Table 56. Baylor Novel Coronavirus (COVID-19) Vaccine Product and Solutions

Table 57. iBio, Inc. Corporate Information, Head Office, and Major Competitors

Table 58. iBio, Inc. Major Business

Table 59. iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions

Table 60. Moderna, Inc. Corporate Information, Head Office, and Major Competitors

Table 61. Moderna, Inc. Major Business

Table 62. Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Product and Solutions

Table 63. Curevac Corporate Information, Head Office, and Major Competitors

Table 64. Curevac Major Business

Table 65. Curevac Novel Coronavirus (COVID-19) Vaccine Product and Solutions

Table 66. ImmunoPrecise Corporate Information, Head Office, and Major Competitors

Table 67. ImmunoPrecise Major Business

Table 68. ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Product and Solutions

Table 69. Global Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million) by Players (2022 & 2028)

Table 70. Global Novel Coronavirus (COVID-19) Vaccine Revenue Share by Players (2022 & 2028)

Table 71. Novel Coronavirus (COVID-19) Vaccine Players Head Office, Products and Services Provided

Table 72. Novel Coronavirus (COVID-19) Vaccine Mergers & Acquisitions in the Past Five Years

Table 73. Novel Coronavirus (COVID-19) Vaccine New Entrants and Expansion Plans

Table 74. Global Market Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million) Comparison by Region (2022 VS 2028)

Table 75. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Region (2022-2028)

Table 76. Key Companies of Novel Coronavirus (COVID-19) Vaccine in North America

Table 77. Current Situation and Forecast of Novel Coronavirus (COVID-19) Vaccine in North America

Table 78. Key Companies of Novel Coronavirus (COVID-19) Vaccine in Europe

Table 79. Current Situation and Forecast of Novel Coronavirus (COVID-19) Vaccine in Europe

Table 80. Key Companies of Novel Coronavirus (COVID-19) Vaccine in Asia-Pacific

Table 81. Current Situation and Forecast of Novel Coronavirus (COVID-19) Vaccine in Asia-Pacific

Table 82. Key Companies of Novel Coronavirus (COVID-19) Vaccine in China

Table 83. Key Companies of Novel Coronavirus (COVID-19) Vaccine in Japan

Table 84. Key Companies of Novel Coronavirus (COVID-19) Vaccine in South Korea

Table 85. Key Companies of Novel Coronavirus (COVID-19) Vaccine in South America

Table 86. Current Situation and Forecast of Novel Coronavirus (COVID-19) Vaccine in South America

Table 87. Key Companies of Novel Coronavirus (COVID-19) Vaccine in Middle East & Africa

Table 88. Current Situation and Forecast of Novel Coronavirus (COVID-19) Vaccine in Middle East & Africa

Table 89. Global Novel Coronavirus (COVID-19) Vaccine Revenue Forecast by Type (2022-2028)

Table 90. Global Novel Coronavirus (COVID-19) Vaccine Revenue Forecast by Application (2022-2028)

List of Figures

Figure 1. Novel Coronavirus (COVID-19) Vaccine Picture

Figure 2. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Type in 2028

Figure 3. DNA

Figure 4. RNA

Figure 5. Others

Figure 6. Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Application in 2028

Figure 7. Mild Symptom Patient Picture

Figure 8. Critically Ill Patient Picture

Figure 9. Global Novel Coronavirus (COVID-19) Vaccine Market Size, (USD Million): 2022 VS 2028

Figure 10. Global Novel Coronavirus (COVID-19) Vaccine Revenue and Forecast (2022-2028) & (USD Million)

Figure 11. Novel Coronavirus (COVID-19) Vaccine Market Drivers

Figure 12. Novel Coronavirus (COVID-19) Vaccine Market Restraints

Figure 13. Novel Coronavirus (COVID-19) Vaccine Market Trends

Figure 14. Inovio Pharmaceuticals Recent Developments and Future Plans

Figure 15. Takis Biotech (Evvivax) Recent Developments and Future Plans

Figure 16. Zydus Cadila Recent Developments and Future Plans

Figure 17. Codagenix, Inc. Recent Developments and Future Plans

Figure 18. GeoVax, Inc. Recent Developments and Future Plans

Figure 19. Bravovax Recent Developments and Future Plans

Figure 20. Janssen Pharmaceutical Companies Recent Developments and Future Plans

Figure 21. Altimmune Recent Developments and Future Plans

Figure 22. Vaxart Recent Developments and Future Plans

Figure 23. CanSino Biologics Recent Developments and Future Plans

Figure 24. ExpreS2ion Biotechnologies ApS Recent Developments and Future Plans

Figure 25. Clover Biopharmaceuticals Recent Developments and Future Plans

Figure 26. GSK Recent Developments and Future Plans

Figure 27. Vaxil Bio Ltd. Recent Developments and Future Plans

Figure 28. Generex Recent Developments and Future Plans

Figure 29. Novavax, Inc. Recent Developments and Future Plans

Figure 30. Sanofi Pasteur Recent Developments and Future Plans

Figure 31. Baylor Recent Developments and Future Plans

Figure 32. iBio, Inc. Recent Developments and Future Plans

Figure 33. Moderna, Inc. Recent Developments and Future Plans

Figure 34. Curevac Recent Developments and Future Plans

Figure 35. ImmunoPrecise Recent Developments and Future Plans

Figure 36. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Region (2022-2028)

Figure 37. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Region in 2028

Figure 38. North America Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million) and Growth Rate (2022-2028)

Figure 39. Europe Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million) and Growth Rate (2022-2028)

Figure 40. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million) and Growth Rate (2022-2028)

Figure 41. South America Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million) and Growth Rate (2022-2028)

Figure 42. Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Revenue (USD Million) and Growth Rate (2022-2028)

Figure 43. Global Novel Coronavirus (COVID-19) Vaccine Market Share Forecast by Type (2022-2028)

Figure 44. Global Novel Coronavirus (COVID-19) Vaccine Market Share Forecast by Application (2022-2028)

Figure 45. Methodology

Figure 46. Research Process and Data Source